CRA’s Life Sciences Practice was retained by a biotechnology company to perform a valuation of its gene editing patent portfolio, and to provide recommendations regarding potential licensing agreements with other companies. CRA developed a valuation model based on publicly available information relating to market opportunities, potential sales, and various risk factors for products in the field of human therapeutics. In addition to assisting the company in assessing the market potential for the use of the relevant patents in the fields of agriculture and research tools. CRA provided recommendations regarding the optimal royalty structure to include in potential future licensing agreements.
IP Literature Watch: March 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...